Helius Therapeutics is New Zealand's largest GMP certified medicinal cannabis company, dedicated to unlocking the therapeutic potential of cannabis to enhance quality of life. With a bold vision, they aim to become a global leader in the research, development, and distribution of next-generation cannabinoid medicines. Their team of scientists is innovating to create the safest and most effective cannabis products in various therapy areas, including symptom relief and disease modification for inflammatory and neurodegenerative conditions.

Recognizing the social and economic opportunities of medical cannabis, Helius Therapeutics is dedicated to improving accessibility. With favorable funding programs and a collaborative scientific community in New Zealand, they serve as an ideal innovation hub for the Asia-Pacific region. As a pioneer in their field, Helius became the first medicinal cannabis company in New Zealand to be GMP certified and gain a License to Manufacture Medicines.

Operating at scale, their state-of-the-art 8,800sqm integrated facility in Auckland enables every stage of the production process, from cultivation and research to manufacturing and distribution. With complete control over the supply chain, Helius ensures the highest standards of quality and consistency in their products. With a focus on research and development, Helius is committed to advancing the field of medicinal cannabis.

Their ongoing research encompasses genetics, novel delivery systems, and clinical trials to develop safe and effective cannabis products. Harnessing the therapeutic potential of New Zealand-grown cannabis, their dedicated R&D team strives to meet the growing demand for nutraceuticals and contribute to the global cannabis innovation landscape. Helius Therapeutics operates under GMP certification, guaranteeing the consistency, safety, and reliability of their products.

Committed to quality, their products undergo rigorous testing for purity, cannabinoid concentration, and stability. With complete traceability from plant to package, Helius ensures traceability and accountability in every batch. Led by a diverse and experienced board, including Chair Candace Kinser and Independent Director Dr.

Rick Acland, Helius Therapeutics combines expertise from various sectors to drive their mission forward. In summary, Helius Therapeutics is at the forefront of the medicinal cannabis industry in New Zealand. With their cutting-edge facilities, commitment to research and development, and dedication to quality, they are shaping the future of cannabis-based medicine and improving accessibility for patients in need